| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 93 | 2024 | 102 | 26.820 |
Why?
|
| Factor VIII | 48 | 2024 | 51 | 10.590 |
Why?
|
| Hemorrhage | 45 | 2024 | 70 | 8.270 |
Why?
|
| Antibodies, Bispecific | 16 | 2023 | 18 | 5.210 |
Why?
|
| Hemophilia B | 20 | 2023 | 22 | 4.670 |
Why?
|
| Antibodies, Monoclonal, Humanized | 20 | 2023 | 70 | 4.330 |
Why?
|
| Recombinant Proteins | 20 | 2024 | 72 | 3.650 |
Why?
|
| Recombinant Fusion Proteins | 19 | 2023 | 34 | 3.550 |
Why?
|
| Quality of Life | 21 | 2024 | 170 | 3.290 |
Why?
|
| Humans | 125 | 2024 | 14077 | 3.150 |
Why?
|
| Genetic Therapy | 14 | 2024 | 35 | 3.010 |
Why?
|
| Factor IX | 18 | 2023 | 18 | 2.970 |
Why?
|
| Immunoglobulin Fc Fragments | 14 | 2023 | 22 | 2.960 |
Why?
|
| Factor VIIa | 12 | 2024 | 13 | 2.660 |
Why?
|
| Adult | 59 | 2024 | 5664 | 2.300 |
Why?
|
| Male | 60 | 2024 | 6489 | 2.030 |
Why?
|
| Young Adult | 40 | 2024 | 2357 | 1.890 |
Why?
|
| Hemarthrosis | 7 | 2022 | 7 | 1.890 |
Why?
|
| Adolescent | 38 | 2024 | 2858 | 1.880 |
Why?
|
| Blood Coagulation Factors | 9 | 2024 | 16 | 1.870 |
Why?
|
| Coagulants | 8 | 2024 | 10 | 1.820 |
Why?
|
| Middle Aged | 41 | 2024 | 3425 | 1.700 |
Why?
|
| Child | 34 | 2024 | 2180 | 1.700 |
Why?
|
| Anemia, Iron-Deficiency | 4 | 2022 | 21 | 1.650 |
Why?
|
| Hemostasis | 11 | 2021 | 15 | 1.620 |
Why?
|
| von Willebrand Diseases | 2 | 2024 | 8 | 1.550 |
Why?
|
| Hemostatics | 8 | 2023 | 17 | 1.520 |
Why?
|
| Half-Life | 15 | 2023 | 21 | 1.510 |
Why?
|
| Treatment Outcome | 22 | 2024 | 867 | 1.410 |
Why?
|
| Aged | 27 | 2021 | 1650 | 1.290 |
Why?
|
| Anemia | 4 | 2022 | 41 | 1.060 |
Why?
|
| Isoantibodies | 7 | 2019 | 15 | 1.010 |
Why?
|
| von Willebrand Factor | 4 | 2021 | 21 | 0.940 |
Why?
|
| Female | 36 | 2023 | 8751 | 0.930 |
Why?
|
| Blood Coagulation Tests | 3 | 2021 | 23 | 0.850 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.830 |
Why?
|
| Capacity Building | 2 | 2019 | 32 | 0.820 |
Why?
|
| Safety | 4 | 2018 | 34 | 0.820 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 532 | 0.810 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 220 | 0.760 |
Why?
|
| Biomarkers | 8 | 2022 | 322 | 0.760 |
Why?
|
| Coombs Test | 1 | 2020 | 1 | 0.740 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2020 | 2 | 0.740 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2020 | 5 | 0.740 |
Why?
|
| Blood Coagulation Disorders, Inherited | 2 | 2019 | 2 | 0.710 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2020 | 6 | 0.700 |
Why?
|
| Health Status | 3 | 2021 | 111 | 0.690 |
Why?
|
| Home Care Services | 1 | 2019 | 15 | 0.660 |
Why?
|
| Hemoglobins | 2 | 2018 | 40 | 0.660 |
Why?
|
| Immunoturbidimetry | 1 | 2019 | 3 | 0.650 |
Why?
|
| Prospective Studies | 10 | 2022 | 1131 | 0.650 |
Why?
|
| Plasma Exchange | 1 | 2018 | 2 | 0.640 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 7 | 0.630 |
Why?
|
| HIV Infections | 3 | 2022 | 4946 | 0.610 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 56 | 0.610 |
Why?
|
| Polyethylene Glycols | 5 | 2021 | 48 | 0.580 |
Why?
|
| Health Personnel | 1 | 2019 | 229 | 0.570 |
Why?
|
| Hemostasis, Surgical | 2 | 2016 | 2 | 0.560 |
Why?
|
| Reticulocytes | 2 | 2018 | 5 | 0.560 |
Why?
|
| South Africa | 21 | 2022 | 7312 | 0.550 |
Why?
|
| Inpatients | 1 | 2015 | 30 | 0.510 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 35 | 0.510 |
Why?
|
| Family Health | 2 | 2015 | 16 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 68 | 0.500 |
Why?
|
| Genetic Counseling | 1 | 2015 | 14 | 0.490 |
Why?
|
| Genetic Testing | 1 | 2015 | 33 | 0.490 |
Why?
|
| Antibodies, Neutralizing | 7 | 2022 | 285 | 0.440 |
Why?
|
| Animals | 6 | 2020 | 1063 | 0.440 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 210 | 0.430 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 153 | 0.430 |
Why?
|
| Disease Management | 6 | 2020 | 73 | 0.420 |
Why?
|
| Retrospective Studies | 6 | 2020 | 767 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 235 | 0.410 |
Why?
|
| Time Factors | 5 | 2024 | 503 | 0.400 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 230 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 124 | 0.400 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2023 | 5 | 0.390 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 1377 | 0.370 |
Why?
|
| Child, Preschool | 11 | 2020 | 1675 | 0.370 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2023 | 5 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 237 | 0.370 |
Why?
|
| Standard of Care | 2 | 2022 | 28 | 0.360 |
Why?
|
| Injections, Subcutaneous | 5 | 2023 | 22 | 0.330 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 243 | 0.320 |
Why?
|
| Serum Albumin | 3 | 2021 | 6 | 0.320 |
Why?
|
| Hematologic Agents | 1 | 2008 | 2 | 0.300 |
Why?
|
| Dependovirus | 3 | 2022 | 8 | 0.300 |
Why?
|
| Registries | 3 | 2024 | 89 | 0.300 |
Why?
|
| Erythrocytes | 1 | 2008 | 11 | 0.300 |
Why?
|
| Blood Sedimentation | 1 | 2008 | 12 | 0.300 |
Why?
|
| Hematology | 1 | 2008 | 4 | 0.300 |
Why?
|
| Hepacivirus | 3 | 2015 | 37 | 0.300 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 59 | 0.280 |
Why?
|
| Blood Coagulation Factor Inhibitors | 2 | 2018 | 4 | 0.270 |
Why?
|
| Ferritins | 3 | 2022 | 23 | 0.270 |
Why?
|
| Developing Countries | 3 | 2024 | 385 | 0.260 |
Why?
|
| Life Expectancy | 3 | 2021 | 31 | 0.250 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 271 | 0.250 |
Why?
|
| Iron | 2 | 2022 | 32 | 0.250 |
Why?
|
| Genetic Vectors | 2 | 2022 | 54 | 0.240 |
Why?
|
| Linear Models | 2 | 2019 | 82 | 0.230 |
Why?
|
| Hepatocytes | 1 | 2024 | 19 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 10 | 0.230 |
Why?
|
| Double-Blind Method | 5 | 2022 | 263 | 0.220 |
Why?
|
| Thromboembolism | 1 | 2023 | 10 | 0.220 |
Why?
|
| Thrombosis | 2 | 2021 | 47 | 0.220 |
Why?
|
| Gene Transfer Techniques | 1 | 2023 | 5 | 0.210 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 183 | 0.210 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 6 | 0.210 |
Why?
|
| Bone Marrow | 1 | 2022 | 19 | 0.210 |
Why?
|
| Erythrocyte Indices | 2 | 2021 | 7 | 0.210 |
Why?
|
| Lipoproteins | 1 | 2022 | 13 | 0.210 |
Why?
|
| Delphi Technique | 2 | 2019 | 28 | 0.210 |
Why?
|
| Hematologic Tests | 2 | 2015 | 11 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 13 | 0.200 |
Why?
|
| Perioperative Care | 3 | 2021 | 8 | 0.200 |
Why?
|
| Pilot Projects | 1 | 2022 | 168 | 0.200 |
Why?
|
| Africa South of the Sahara | 2 | 2019 | 328 | 0.200 |
Why?
|
| Heterozygote | 1 | 2021 | 42 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 16 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 137 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 20 | 0.180 |
Why?
|
| Immune Tolerance | 2 | 2018 | 22 | 0.180 |
Why?
|
| Europe | 3 | 2022 | 53 | 0.180 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hepcidins | 1 | 2020 | 6 | 0.180 |
Why?
|
| Models, Biological | 2 | 2018 | 77 | 0.180 |
Why?
|
| Blood Loss, Surgical | 2 | 2019 | 5 | 0.170 |
Why?
|
| Joint Diseases | 2 | 2017 | 3 | 0.170 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hospitalization | 2 | 2019 | 392 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 112 | 0.170 |
Why?
|
| Work | 1 | 2019 | 9 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 11 | 0.160 |
Why?
|
| Absenteeism | 1 | 2019 | 10 | 0.160 |
Why?
|
| Research Design | 1 | 2020 | 123 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 6 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 20 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 21 | 0.160 |
Why?
|
| Thrombin | 2 | 2023 | 8 | 0.160 |
Why?
|
| Renal Dialysis | 1 | 2018 | 25 | 0.160 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 14 | 0.160 |
Why?
|
| Schools | 1 | 2019 | 67 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 57 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 2018 | 2 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 78 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2015 | 100 | 0.150 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 15 | 0.150 |
Why?
|
| Joints | 1 | 2017 | 9 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2018 | 120 | 0.150 |
Why?
|
| Research | 1 | 2018 | 65 | 0.150 |
Why?
|
| Australia | 2 | 2015 | 46 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2019 | 137 | 0.150 |
Why?
|
| Mutation | 2 | 2015 | 299 | 0.140 |
Why?
|
| Prevalence | 1 | 2020 | 1149 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2015 | 217 | 0.140 |
Why?
|
| Swine | 1 | 2016 | 49 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Phenotype | 4 | 2023 | 144 | 0.130 |
Why?
|
| Infant | 5 | 2020 | 2145 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2016 | 11 | 0.130 |
Why?
|
| Placebos | 2 | 2015 | 44 | 0.130 |
Why?
|
| Demography | 1 | 2016 | 105 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 251 | 0.130 |
Why?
|
| Viral Core Proteins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2015 | 4 | 0.130 |
Why?
|
| HLA-D Antigens | 1 | 2015 | 2 | 0.130 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 27 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 22 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 63 | 0.130 |
Why?
|
| Antibody Specificity | 1 | 2015 | 30 | 0.130 |
Why?
|
| Cross Reactions | 1 | 2015 | 44 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2014 | 55 | 0.130 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 139 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 18 | 0.120 |
Why?
|
| Neutralization Tests | 1 | 2015 | 106 | 0.120 |
Why?
|
| Epitopes | 1 | 2015 | 97 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 13 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2014 | 33 | 0.120 |
Why?
|
| Capital Financing | 1 | 2014 | 1 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 168 | 0.120 |
Why?
|
| Physician's Role | 1 | 2014 | 8 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2018 | 542 | 0.110 |
Why?
|
| RNA, Viral | 2 | 2015 | 303 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 41 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 367 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2022 | 16 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 8 | 0.110 |
Why?
|
| Risk Factors | 5 | 2016 | 1431 | 0.110 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 13 | 0.100 |
Why?
|
| Prothrombin Time | 1 | 2012 | 15 | 0.100 |
Why?
|
| Brazil | 2 | 2022 | 43 | 0.100 |
Why?
|
| Autoantibodies | 3 | 2021 | 47 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2011 | 1 | 0.100 |
Why?
|
| Inverted Repeat Sequences | 1 | 2011 | 3 | 0.090 |
Why?
|
| United States | 2 | 2022 | 129 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 123 | 0.090 |
Why?
|
| Communication | 2 | 2021 | 56 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2011 | 169 | 0.090 |
Why?
|
| Genotype | 4 | 2015 | 430 | 0.080 |
Why?
|
| Blood Cell Count | 1 | 2009 | 15 | 0.080 |
Why?
|
| Consensus | 2 | 2020 | 59 | 0.080 |
Why?
|
| Self Report | 2 | 2021 | 111 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Drug Utilization | 1 | 2008 | 10 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 37 | 0.080 |
Why?
|
| Factor V Deficiency | 1 | 2008 | 1 | 0.080 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mannose-Binding Lectins | 1 | 2008 | 2 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2008 | 89 | 0.080 |
Why?
|
| Laboratories, Hospital | 1 | 2008 | 2 | 0.080 |
Why?
|
| Automation | 1 | 2008 | 8 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2008 | 34 | 0.070 |
Why?
|
| National Health Programs | 1 | 2008 | 78 | 0.070 |
Why?
|
| Factor VIIIa | 1 | 2023 | 1 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 939 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2023 | 1 | 0.050 |
Why?
|
| Base Sequence | 2 | 2015 | 149 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 17 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 263 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 110 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 11 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2022 | 21 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 23 | 0.050 |
Why?
|
| India | 1 | 2022 | 60 | 0.050 |
Why?
|
| International Cooperation | 1 | 2022 | 50 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2022 | 52 | 0.050 |
Why?
|
| Syndrome | 1 | 2021 | 19 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 104 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 22 | 0.050 |
Why?
|
| Inflammation | 1 | 2022 | 103 | 0.050 |
Why?
|
| Serogroup | 1 | 2022 | 134 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2001 | 12 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2001 | 14 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2013 | 65 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 8 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2021 | 64 | 0.050 |
Why?
|
| ROC Curve | 1 | 2020 | 47 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2020 | 2 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 184 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 266 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 252 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 206 | 0.040 |
Why?
|
| Health Care Sector | 1 | 2019 | 8 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 8 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 449 | 0.040 |
Why?
|
| Developed Countries | 1 | 2019 | 23 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 32 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 183 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 235 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 4 | 0.040 |
Why?
|
| Transferrin | 1 | 2018 | 5 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2017 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 380 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 1410 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 4 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sequence Analysis, Protein | 1 | 2015 | 10 | 0.030 |
Why?
|
| Interferons | 1 | 2015 | 9 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2015 | 12 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 15 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 163 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 43 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 26 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 117 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2015 | 37 | 0.030 |
Why?
|
| North America | 1 | 2015 | 11 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2015 | 50 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 19 | 0.030 |
Why?
|
| China | 1 | 2015 | 21 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 4 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 7 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 107 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 34 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 12 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 145 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 17 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 53 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2008 | 165 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 131 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 655 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 364 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 22 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2015 | 268 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2013 | 27 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 119 | 0.030 |
Why?
|
| Immunization | 1 | 2013 | 63 | 0.030 |
Why?
|
| Pain Management | 1 | 2012 | 12 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 5 | 0.030 |
Why?
|
| Hematinics | 1 | 2011 | 1 | 0.020 |
Why?
|
| Iron Chelating Agents | 1 | 2011 | 7 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 3 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 154 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2011 | 11 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 59 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 197 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 105 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 64 | 0.020 |
Why?
|
| COS Cells | 1 | 2008 | 2 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2008 | 5 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 224 | 0.020 |
Why?
|
| Factor V | 1 | 2008 | 10 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2008 | 19 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2008 | 30 | 0.020 |
Why?
|
| Phylogeny | 1 | 2008 | 231 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 654 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 79 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 260 | 0.010 |
Why?
|